F
François Raffi
Researcher at French Institute of Health and Medical Research
Publications - 353
Citations - 12355
François Raffi is an academic researcher from French Institute of Health and Medical Research. The author has contributed to research in topics: Population & Medicine. The author has an hindex of 52, co-authored 315 publications receiving 10653 citations. Previous affiliations of François Raffi include Hotel Dieu Hospital & University of Nantes.
Papers
More filters
Journal ArticleDOI
Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era.
Olivier Sitbon,Caroline Lascoux-Combe,Jean-François Delfraissy,Patrick Yeni,François Raffi,Dominique De Zuttere,Virginie Gressin,Pierre Clerson,Daniel Sereni,Gérald Simonneau +9 more
TL;DR: Given the current good long-term prognosis of patients with HIV, the severity of PAH in HIV-infected patients, and the absence of predictive factors, careful screening for PAH is warranted for patients with unexplained dyspnea.
Journal ArticleDOI
Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study
Fabrice Carrat,Hélène Fontaine,Céline Dorival,Mélanie Simony,Alpha Diallo,Christophe Hézode,Victor de Ledinghen,Dominique Larrey,Georges Haour,Jean-Pierre Bronowicki,Fabien Zoulim,Tarik Asselah,Patrick Marcellin,Dominique Thabut,Vincent Leroy,Albert Tran,François Habersetzer,Didier Samuel,Dominique Guyader,Olivier Chazouillères,Philippe Mathurin,Sophie Metivier,Laurent Alric,Ghassan Riachi,Jérôme Gournay,Armand Abergel,Paul Calès,Nathalie Ganne,Véronique Loustaud-Ratti,Louis d’Alteroche,Xavier Causse,Claire Geist,Anne Minello,Isabelle Rosa,Moana Gelu-Simeon,Isabelle Portal,François Raffi,Marc Bourlière,Stanislas Pol +38 more
TL;DR: Treatment with direct-acting antivirals is associated with reduced risk for mortality and hepatocellular carcinoma and should be considered in all patients with chronic HCV infection.
Journal ArticleDOI
Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population.
Marianne Savès,Geneviève Chêne,Pierre Ducimetière,Catherine Leport,Gwenael Le Moal,Philippe Amouyel,Dominique Arveiler,Jean-Bernard Ruidavets,Jacques Reynes,Annie Bingham,François Raffi,French Who Monica +11 more
TL;DR: Because most HIV-1-infected people will ultimately need antiretroviral therapy, risk factors for cardiovascular disease should be determined at the initiation of treatment, and interventions should be considered for all patients who have them.
Journal ArticleDOI
European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults
TL;DR: This third version of the EACS guidelines includes, as new topics, the assessment of patients at initial and subsequent clinic visits as well as post‐exposure prophylaxis in the treatment of adults with HIV infection.
Journal ArticleDOI
Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial
François Raffi,Hans Jaeger,Eugenia Quiros-Roldan,Helmut Albrecht,Elena Belonosova,José M. Gatell,Jean-Guy Baril,Pere Domingo,Clare Brennan,Steve Almond,Sherene Min +10 more
TL;DR: Once-daily dosing without requirement for a pharmacokinetic booster makes dolutegravir-based therapy an attractive treatment option for HIV-1-infected treatment-naive patients.